E Noris-García1, S Arce1, P Nardin2, M E Lanigan3, V Acuña3, F Gutierrez3, M A Robinson-Agramonte4, C-A Gonçalves5. 1. 1 Department of Immunology, Nephrology Institute, Havana, Cuba. 2. 2 Faculty of Pharmaceutical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 3. 3 Department of Psychiatric, Joaquín Albarrán Hospital, Havana, Cuba. 4. 4 Department of Neuroimmunology, International Center for Neurological Restoration, Havana, Cuba. 5. 5 Department of Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Abstract
BACKGROUND: The aim of this study was to investigate serum S100B and brain-derived neurotrophic factor (BDNF) in systemic lupus erythematous (SLE) patients, with and without neuropsychiatric (NP) manifestation activity. METHODS: We assessed 47 SLE patients and 20 selected healthy individuals. Disease activity was assessed according to the SLE disease activity index (SLEDAI). Serum BDNF and S100B were measured by enzyme-linked immunosorbent assay. RESULTS: Serum S100B protein was significantly higher in SLE patients. BDNF levels were significantly decreased in active SLE, when compared with inactive SLE, but not when compared with controls. S100B was clearly higher in the NPSLE group, when compared with the non-NPSLE or control groups. Receiver operating characteristic analysis of S100B revealed an area under the curve of 0.706 that discriminated NPSLE patients with peripheral polyneuropathy. CONCLUSIONS: Our findings reinforce the use of serum S100B as a biomarker in SLE, particularly for NPSLE. Moreover, we found a strong association between serum S100B and peripheral neuropathy, indicating a specific utility for this biomarker in SLE that warrants clinical investigation.
BACKGROUND: The aim of this study was to investigate serum S100B and brain-derived neurotrophic factor (BDNF) in systemic lupus erythematous (SLE) patients, with and without neuropsychiatric (NP) manifestation activity. METHODS: We assessed 47 SLEpatients and 20 selected healthy individuals. Disease activity was assessed according to the SLE disease activity index (SLEDAI). Serum BDNF and S100B were measured by enzyme-linked immunosorbent assay. RESULTS: Serum S100B protein was significantly higher in SLEpatients. BDNF levels were significantly decreased in active SLE, when compared with inactive SLE, but not when compared with controls. S100B was clearly higher in the NPSLE group, when compared with the non-NPSLE or control groups. Receiver operating characteristic analysis of S100B revealed an area under the curve of 0.706 that discriminated NPSLE patients with peripheral polyneuropathy. CONCLUSIONS: Our findings reinforce the use of serum S100B as a biomarker in SLE, particularly for NPSLE. Moreover, we found a strong association between serum S100B and peripheral neuropathy, indicating a specific utility for this biomarker in SLE that warrants clinical investigation.
Authors: Helena Alessi; Lívia Almeida Dutra; Lília A Maria; Paula C Coube; Karina Hoshino; Fabiano F de Abrantes; Fernanda C Lopes; Alexandre Wagner S de Souza; Cristiane Kayser; Orlando G P Barsottini Journal: Clin Rheumatol Date: 2021-09-19 Impact factor: 2.980
Authors: Maria de Los Angeles Robinson-Agramonte; Carlos-Alberto Gonçalves; Roberto Farina de Almeida; Alina González Quevedo; Sandra Chow; Luis Velázquez Pérez; Amado Díaz de la Fé; Patricia Sesterheim; Diogo Onofre Gomes Souza Journal: Behav Sci (Basel) Date: 2019-09-12